Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

BeOne Medicines (BEIGF) Return on Equity (2016 - 2025)

Historic Return on Equity for BeOne Medicines (BEIGF) over the last 10 years, with Q3 2025 value amounting to 0.02%.

  • BeOne Medicines' Return on Equity rose 2700.0% to 0.02% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.02%, marking a year-over-year increase of 2700.0%. This contributed to the annual value of 0.19% for FY2024, which is 300.0% up from last year.
  • As of Q3 2025, BeOne Medicines' Return on Equity stood at 0.02%, which was up 2700.0% from 0.05% recorded in Q2 2025.
  • BeOne Medicines' Return on Equity's 5-year high stood at 0.02% during Q3 2025, with a 5-year trough of 0.45% in Q1 2023.
  • For the 5-year period, BeOne Medicines' Return on Equity averaged around 0.28%, with its median value being 0.3% (2021).
  • Its Return on Equity has fluctuated over the past 5 years, first soared by 3000bps in 2021, then tumbled by -1400bps in 2022.
  • Over the past 5 years, BeOne Medicines' Return on Equity (Quarter) stood at 0.3% in 2021, then crashed by -46bps to 0.44% in 2022, then soared by 46bps to 0.24% in 2023, then rose by 21bps to 0.19% in 2024, then surged by 109bps to 0.02% in 2025.
  • Its Return on Equity was 0.02% in Q3 2025, compared to 0.05% in Q2 2025 and 0.11% in Q1 2025.